The UK Health Security Agency (UKHSA) has published the latest national surveillance data on antibiotic prescribing and resistance.
The English surveillance programme for antimicrobial utilisation and resistance (ESPAUR) report showed an increase in antibiotic use in all settings
(apart from dental) in 2022.
According to the report, antibiotic prescribing rose by 8.4 per cent in 2022 compared with 2021, although the number remains below 2019 pre-pandemic levels.
"There are many reasons behind the increase in prescribing, one of which is likely related to decreased immunity and exposure to infections during the
COVID-19 pandemic that may have underpinned the increased transmission in co-circulating infections, namely: influenza (flu), respiratory syncytial virus
(RSV) and group A streptococcus (GAS)," the report stated.
Two new medications which fight drug-resistant superbugs could soon become available to NHS patients in England after the National Institute for Health and Care Excellence (NICE) said they offered value for money.
NICE said Cefiderocol and ceftazidime-avibactam will be the first antimicrobial drugs to be made available as part of a subscription-style payment model that incentivises research and development of antimicrobials by testing new approaches to evaluating and paying for them.
As part of part of a project with the NHS and the Department of Health and Social Care, the new payment model is designed to address the growing threat posed by antimicrobial resistance - a serious global problem - which develops when the pathogens that cause infection evolve to make antibiotics and other antimicrobial
drugs less effective or stop them from working altogether.